Laboratory testing in monoclonal gammopathy of renal significance (MGRS).
Leung N et al. Clin Chem Lab Med. 2016 Apr 23. pii: /j/cclm.ahead-of-print/cclm-2015-0994/cclm-2015-0994.xml. doi: 10.1515/cclm-2015-0994. [Epub ahead of print].
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach.
Sivaraj D et al. Clin Lymphoma Myeloma Leuk. 2016 Mar 29. pii: S2152-2650(16)30014-3. doi: 10.1016/j.clml.2016.03.002. [Epub ahead of print].
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH et al. Clin Lymphoma Myeloma Leuk. 2016 Mar 29. pii: S2152-2650(16)30017-9. doi: 10.1016/j.clml.2016.03.005. [Epub ahead of print].
Phenotypic, transcriptomic and genomic features of clonal plasma cells in light chain amyloidosis.
Paiva B et al. Blood. 2016 Apr 11. pii: blood-2015-10-673095. [Epub ahead of print].
Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center.
Li XM et al. Ann Hematol. 2016 Apr 8. [Epub ahead of print].
Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P et al. Curr Treat Options Oncol. 2016 Apr;17(4):19. doi: 10.1007/s11864-016-0392-6.